Ignite Creation Date:
2024-05-06 @ 6:52 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05817149
Status:
COMPLETED
Last Update Posted:
2023-04-18
First Post:
2023-04-05
Brief Title:
Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma a Pilot Study
Sponsor:
Aalborg University Hospital
Organization:
Aalborg University Hospital
Study Overview
Official Title:
Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma a Pilot Study
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We want to test if an association between sentinel lymph node biopsy SLBN and a systemic inflammatory response can be made
Detailed Description:
Sentinel lymph node biopsy SLBN is essential in staging melanoma and properly selecting patients for adjuvant immunotherapy However surgically induced inflammation can potentially aid in progression of remaining malignant cells and affect prognosis The inflammatory marker neutrophil-to-lymphocyte ratio NLR is also a negative prognostic and predictive marker in serval malignancies among melanoma However it is not yet established if SLNB induces a systemic inflammatory response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None